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valvular heart diseaseNiv Ad, MDSee related article on pages 3194-201.In this issue of the Journal, Brizard and colleagues1 report
the results of their use of a new engineered treatment of
bovine pericardium in valve surgery. In this study, the
investigators replaced the posterior leaflet of the mitral
valve, as well as one of the leaflets of the pulmonary valve,
with CardioCel (Admedus Ltd, Perth, Australia), a chemi-
cally engineered bovine pericardium, and compared the
engineered tissue with glutaraldehyde-treated autologous
pericardium in a juvenile sheep model.
Brizard and colleagues1 report that the use of the
CardioCel bovine patch in a widely used and challenging
growing lamb model resulted in durable valve repair in
both the mitral and the pulmonary positions for as long as
7 months after the procedure. In their hands, the mechanical
properties of the patch were preserved. Interestingly, the
treated bovine pericardium exhibited controlled healing
without significant calcification and demonstrated better
performance than did the autologous pericardium.
In the search for a durable valve prosthesis that will yield
stable results and very little deterioration over time, Brizard
and colleagues1 have made a valuable contribution. The
challenges presented by this quest are especially daunting
in pediatric populations. Unlike valve surgery in adults,
repairs of congenital valve deformities require very small
valve sizes, which are not currently commercially available.
Adding to the conundrum that is inherent in the use of exist-
ing mechanical and biological prostheses in pediatric
patients is the failure of these devices to grow, repair, and
remodel.2 It is therefore possible that tissue-engineered
heart valves and patches offer a promising solution to these
challenges. Brizard and colleagues1 add important informa-
tion to what is currently known about the behavior of the
CardioCel bovine patch in comparison with that of autolo-
gous pericardium.
An interesting question posed by this study is whether the
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3202 The Journal of Thoracic and Cardiovascular SurBrizard and colleagues1 are clear that autologous pericar-
dium is readily available and is being widely used. The
long-term success of any patch used in this context is neces-
sarily related to the amount of calcium deposits, the healing
process, and tissue strength and growth. Previous studies
have identified several major variables that are associated
with tissue calcification, degeneration, and lack of microen-
vironment for host progenitor cell migration in tissue
implants—namely, cellular antigens, circulating calcium
ions, phospholipids present in the native tissue, and glutar-
aldehyde processing. The CardioCel Patch is the result of a
chemically engineered, multistep ADAPT treatment
(Admedus, Perth, Australia) involving multiple factors
that could interferewith the prosthetic’s viability. Other bio-
engineered materials currently being studied use processes
such as lyophilization,3 which has shown promising results
in reducing inflammation. Another proposed approach is
the use of decellularized valves and patches with the prom-
ise of normal remodeling and growth,4 such as extracellular
matrix and its potential for tissue regeneration.5
A previous publication6 has reported promising clinical
outcomes obtained by magnetic resonance imaging and
echocardiography with the use of the CardioCel patch in
30 patients. The results of Brizard and colleagues,1
together with those of other recent publications reporting
positive results with extracellular matrix,7 provide hope
for a breakthrough in the field of bioengineering to further
improve the treatment of heart valve disease. The key
bioengineering challenge is to determine how biologic,
structural, and mechanical factors interact and function
in vivo. The understanding of these factors will prove
critical to the development of a clinically viable tissue-
engineered heart valve.References
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